Presence of phenylethylamine in hallucinogenic Psilocybe mushroom: Possible role in adverse reactions

Journal of Analytical Toxicology

Volumn 22, Issue 1, 1998, Pages 45-49

  Beck, Olof ^a   Helander, Anders ^b   Karlson Stiber, Christine ^a   Stephansson, Nikolai ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ST GÖRAN S HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PHENETHYLAMINE; PSILOCYBINE; PSYCHEDELIC AGENT;

ARTICLE; CHEMICAL ANALYSIS; GAS CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MUSHROOM; MUSHROOM POISONING; SYMPTOMATOLOGY;

EID: 0031932890     PISSN: 01464760     EISSN: None     Source Type: Journal    
DOI: 10.1093/jat/22.1.45     Document Type: Article

References (26)

1. C. Smith and D. Nutbeam. Adolescent drug use in Wales. Brit. J. Addict. 87: 227-233 (1992).
2. J.F. Lassen, N.F. Lassen, and J. Skov. Consumption of hallucinogenic mushrooms containing psilocybine by young people. Ugeskr. Laeger 154: 2678-2681 (1992).
3. J.W. Allen and M.D. Merlin. Psychoactive mushroom use in Koh Samui and Koh Pha-Ngan, Thailand. J. Ethnopharmacol. 35: 205-228 (1992).
4. M.J. Cuomo, P.G. Dyment, and V.M. Gammino. Increasing use of "ectasy" (MDMA) and other hallucinogens on a college campus. J. Amer. Coll. Health 42: 271-274 (1994).
5. E. Webb, C.H. Ashton, P. Kelly, and F. Kamali. Alcohol and drug use in UK university students. Lancet 348: 922-925 (1996).
6. R.H. Schwartz and D.E. Smith. Hallucinogenic mushrooms. Clin. Ped. 27: 70-73 (1988).
7. A.T. Shulgin. Psilocybin. J. Psychedelic Drugs 12: 79 (1980).
8. H.C. Sabelli and J.I. Javaid. Phenylethylamine modulation of affect: therapeutic and diagnostic implications. J. Neuropsychiatry Clin. Neurosci. 7: 6-14 (1995).
9. M.E. Wolf and A.D. Mosnaim. Phenylethylamine in neuropsychiatric disorders. Gen. Pharmacol. 14: 385-390 (1983).
10. R.L. O'Reilly and B.A. Davis. Phenylethylamine and schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 18: 63-75 (1994).
11. J.P. Chaytor, B. Crathorne, and M.J. Saxby. The identification and significance of 2-phenylethylamine in foods. J. Sci. Food Agric. 26: 593-598 (1975).
12. P. Mantegazza and M. Riva. Amphetamine-like activity of β-phenylethylamine after a monoamine oxidase inhibitor in vivo. J. Pharmacol. 15: 472-478 (1963).
13. H.C. Sabelli and W.J. Giardina. Amine modulation of affective behavior. In Chemical Modulation of Brain Function, H.C. Sabelli, Ed., Raven, New York, NY, 1972, pp 225-259.
14. J.M. Saavedra, B. Heller, and E. Fischer. Antagonostic effects of tryptamine and β-phenylethylamine on the behaviour of rodents. Nature 226: 868 (1970).
15. 2 involvement in the mechanism of action of hallucinogenic drugs. Life Sci. 35: 2505-2511 (1984).
16. R.J. Strassman. Human hallucinogen interactions with drugs affecting serotonergic neurotransmission. Neuropsychopharmacology 7: 241-242 (1992).
17. A.J. Goudie and C. Buckland. Serotonin receptor blockade potentiates behavioural effects of beta-phenylethylamine. Neuropharmacology 21: 1267-1272 (1982).
18. E. Ortman and G. Steen. Phenylethylamine - a hazardous substitute for amphetamine in the narcotics market. Läkartidningen 70: 118-119 (1973).
19. N.R. Peden, A.F. Bissett, K.E.C. Macaulay, J. Crooks, and A.J. Pelosi. Clinical toxicology of "magic mushroom" ingestion. Postgrad. Med. J. 57: 543-545 (1981).
20. N.R. Peden, S.D. Pringle, and J. Crooks. The problem of psilocybin mushroom abuse. Hum. Toxicol. 1: 417-424 (1982).
21. S. Malitz, H. Esecover, B. Wilkens, and P.H. Hoch. Some observations on psilocybin, a new hallucinogen, in volunteer subjects. Comp. Psychiatry 1: 8-17 (1960).
22. H. Isbell. Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia 1: 29-38 (1959).
23. L.E. Hollister, J.J. Prusmack, J.A. Paulsen, and N. Rosenquist. Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects. J. Nervous Mental Dis. 131: 428-434 (1960).
24. M.D. Berry, A.V. Juorio, and I.A. Paterson. The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog. Neurobiol. 42: 375-391 (1994).
25. F. Kalberer, W. Kreis, and J. Rutschmann. The fate of psilocin in the rat. Biochem. Pharmacol. 11: 261-269 (1962).
26. D.J. McKenna, G.H.N. Towers, and F. Abbott. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca. J. Ethnopharmacol. 10: 195-223 (1984).